PuSH - Publikationsserver des Helmholtz Zentrums München

Grallert, H. ; Marzi, C. ; Hauck, S.M. ; Gieger, C.

Omics: Potential role in early phase drug development.

In: Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. 2019. 309-347
DOI
Background The development of high-throughput omics technologies has nourished the hope to improve our understanding and treatment of the pathophysiology of globally increasing diseases such as type 2 diabetes, obesity, and nonalcoholic fatty liver disease/ nonalcoholic steatohepatitis (NAFLD/ NASH). These technologies provide innovative tools that have the potential to truly revolutionize patient care. Key Methods (a) Genomics, Epigenomics, Transcriptomics Technologies continue to propel the omics fields forward. However, translating research discovery into routine clinical applications use is a complex process not only from scientific prospective but also from ethical, political, and logistic points of view. Particularly the implementation of omics-based tests requires changes in fundamental processes of regulation, reimbursement, and clinical practice. Altogether, developments in the field of omics technologies hold great promise to optimize patient care and improve outcomes and eventually lead to new tests and treatments that are well integrated in routine medical care of people with obesity, type 2 diabetes and NAFLD/ NASH.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Sammelbandbeitrag/Buchkapitel
Korrespondenzautor
Bandtitel Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease
Quellenangaben Band: , Heft: , Seiten: 309-347 Artikelnummer: , Supplement: ,
Nichtpatentliteratur Publikationen
Institut(e) Institute of Epidemiology II (EPI2)
CF Metabolomics & Proteomics (CF-MPC)